SCHEMBL4804899

SCHEMBL4804899

Nc1cccc(-c2ccnc(C(N)Cc3ccccc3)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.46
CYP17A1 P05093 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
F11 P03951 3/20 0.41
SLC6A2 P23975 2/20 0.41
TAAR1 Q96RJ0 2/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
CYP2A6 P11509 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
MAP4K4 O95819 3/20 0.41
ASIC3 Q9UHC3 1/20 0.41
MEN1 O00255 1/20 0.40
PSIP1 O75475 1/20 0.40
AXL P30530 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2329787 0.90 F11 (0.47) MAOACYP19A1F11SLC6A2TAAR1
SCHEMBL4797888 0.86 GPR142 (0.41) MAOAF11SLC6A2TAAR1SLC6A4
SCHEMBL4806539 0.85 GRIA2 (0.50) MAOACYP17A1CYP3A4CYP19A1CYP11B1
SCHEMBL4804375 0.78 ROCK2 (0.39) MAOAF11SLC6A2TAAR1SLC6A4
SCHEMBL4799486 0.77 CYP17A1 (0.49) CYP17A1CYP11B1CYP11B2F11MAP4K4
SCHEMBL4798617 0.76 F11 (0.57) F11MKNK1MKNK2
SCHEMBL4803126 0.75 F11 (0.57) F11ROCK2
SCHEMBL1196730 0.75 PNMT (0.45) MAOACYP3A4SLC6A2TAAR1SLC6A4
SCHEMBL14063540 0.74 MAP4K4 (0.49) MAOACYP17A1CYP3A4CYP19A1CYP11B1
SCHEMBL4809958 0.74 CYP11B1 (0.47) CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429604-B2 Six-membered heterocycles useful as serine protease inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2008-09-30 US disclosed
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; BRISTOL-MYERS SQUIBB COMPANY 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; F12, F11, F2 MAOA 1197/4885CYP17A1 1461/4885CYP3A4 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.